Does it excite you to work with GMP Quality Assurance for Drug Product and Combination Products in an outsourced development set-up, and do you have experience with QA oversight of CMOs, QP responsibilities, and cross-functional CMC collaboration? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
As our Associate QA Director, you will provide QA oversight and compliant quality guidance for Drug Product and Combination Product development and GMP manufacturing performed at external CMOs and in close collaboration with partners. You will help ensure robust GMP execution and timely quality decisions. In addition, the role contains delegated Qualified Person (QP) responsibilities for both clinical and commercial products, in accordance with applicable GMP legislation. The role also involves occasional travel to support effective oversight and collaboration with external sites. You will join Manufacturing QA in an outsourced business model where strong collaboration and clear quality judgment are key.
We offer exciting responsibilities:
The role suits a quality-minded, collaborative professional who can balance a pragmatic approach with strong compliance judgment and clear stakeholder communication. Success requires the ability to build trusted relationships while maintaining appropriate QA oversight of suppliers and partners in an outsourced set-up.
You will join Manufacturing QA, which provides QA support and oversight across manufacturing-related activities in an outsourced business model. The team works closely with internal development stakeholders as well as external CMOs and partners to ensure compliant execution, robust quality decisions, and readiness for inspections and partner interactions. The position reports to Martin Wallin, Head of Manufacturing QA.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture.
Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.
Interested in bonding with us? Then please apply no later than September 27, 2026, or as soon as possible. The applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.
For further information, please contact Head of Manufacturing QA, Martin Wallin, mwallin@zealandpharma.com.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
#LI-Onsite
At Zealand Pharma, we are a Danish biotechnology company on a mission to change lives with next generation peptide medicines.
In our effort to reach our goals, bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other.
Ten drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Our current pipeline of internal product candidates focuses on obesity, chronic inflammation, and certain rare diseases.
Our leading obesity programs are backed by strong partners, including Roche and Boehringer Ingelheim.
We are based in Copenhagen (Søborg), Denmark, with a team in the U.S. For further information about our business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn.
